Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Temozolomide is named as an intervention in 49 current clinical trials in our USA, China, UK, Ireland and India registers. 29 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Eli Lilly and Company (3). The most-studied condition is Glioblastoma.

Trials by status

Recruiting2959%
Not yet open612%
Active, closed1429%

Trials by phase

Phase 22245%
Phase 1/21020%
Phase 3816%
Phase 1510%
Phase 2/348%

Clinical trials of Temozolomide

49 trials

Study	Phase	Status	Lead sponsor	Registers
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM NCT05902169 · Glioblastoma, Recurrent Glioblastoma, GBM	Phase 3	Recruiting	CarThera	USA
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma NCT06556563 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 3	Recruiting	NovoCure GmbH	UK, USA
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · ClinicalTrials.gov ↗ · Melanoma, Cutaneous Malignant	Phase 3	Recruiting	Immatics US, Inc.	UK, USA
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) NCT07104032 · Relapsed/Refractory Primary Central Nervous System Lymphoma	Phase 3	Recruiting	Ono Pharmaceutical Co., Ltd.	USA
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care NCT07195591 · Glioblastoma	Phase 3	Recruiting	GT Medical Technologies, Inc.	USA
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma NCT06624644 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma	Phase 2/3	Recruiting	Linnaeus Therapeutics, Inc.	USA
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients NCT07549321 · ClinicalTrials.gov ↗ · High-Risk Neuroblastoma	Phase 2/3	Recruiting	Renaissance Pharma Ltd.	UK, USA
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma NCT04737889 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma	Phase 2	Recruiting	Henan Cancer Hospital	China
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma NCT04961515 · ClinicalTrials.gov ↗ · Primary Central Nervous System Hodgkin Lymphoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer NCT05999994 · ClinicalTrials.gov ↗ · Neoplasms, Child, Adolescent	Phase 2	Recruiting	Eli Lilly and Company	UK, USA
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma NCT06013618 · ClinicalTrials.gov ↗ · Neuroblastoma	Phase 2	Recruiting	Sun Yat-Sen University Cancer Center	China
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. NCT06514313 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma	Phase 2	Recruiting	Yizhuo Zhang	China
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) NCT06595186 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme (GBM)	Phase 2	Recruiting	JenKem Technology Co., Ltd.	China
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion NCT06739395 · ClinicalTrials.gov ↗ · Solid Tumor, Precision Medicine	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) NCT06805305 · Glioblastoma (GBM)	Phase 2	Recruiting	Diakonos Oncology Corporation	USA
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma NCT07015242 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	USA
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread NCT07193654 · ClinicalTrials.gov ↗ · Glioblastoma (GBM)	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma NCT07297212 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Recruiting	BioNTech SE	China
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII NCT07326566 · ClinicalTrials.gov ↗ · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM	Phase 2	Recruiting	Black Diamond Therapeutics, Inc.	USA
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery NCT07400302 · ClinicalTrials.gov ↗ · Mucosal Melanoma, PD-L1 Positive	Phase 2	Recruiting	The First Hospital of Jilin University	China
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression NCT07670026 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma NCT04625907 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma	Phase 1/2	Recruiting	University of Birmingham	Ireland
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies NCT05417594 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies	Phase 1/2	Recruiting	AstraZeneca	UK, USA
A Phase 2 Study of HX301 in Patients with High-grade Giloma NCT06703255 · ClinicalTrials.gov ↗ · Glioma	Phase 1/2	Recruiting	Hangzhou Hanx Biopharmaceuticals, Ltd.	China
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas NCT03715933 · ClinicalTrials.gov ↗ · Ewing Sarcoma, Colorectal Adenocarcinoma	Phase 1	Recruiting	Inhibrx Biosciences, Inc	UK, USA
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma NCT05879367 · ClinicalTrials.gov ↗ · Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme	Phase 1	Recruiting	Orbus Therapeutics, Inc.	USA
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer NCT06931626 · Small Cell Lung Cancer	Phase 1	Recruiting	Nerviano Medical Sciences	USA
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma NCT07349693 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma, IDH-Wildtype	Phase 2/3	Not yet open	Everfront Biotech Co., Ltd.	USA
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma NCT07758062 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Not yet open	Tianjin Medical University General Hospital	China
NG101m Adjuvant Therapy in Glioblastoma Patients NCT04373785 · Glioblastoma Multiforme	Phase 1/2	Not yet open	NeuGATE Theranostics	USA
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy NCT07762716 · ClinicalTrials.gov ↗ · Glioblastoma (GBM)	Phase 1/2	Not yet open	BreakBio Corp	USA
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers NCT07811297 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS)	Phase 1/2	Not yet open	Advenchen Pharmaceuticals, LLC.	USA
Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer NCT07732413 · ClinicalTrials.gov ↗ · Progressive Pediatric Brain Cancer	Phase 1	Not yet open	Lumos Pharma	USA
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) NCT00626990 · ClinicalTrials.gov ↗ · Brain and Central Nervous System Tumors	Phase 3	Active, closed	European Organisation for Research and Treatment of Cancer - EORTC	Ireland
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme NCT02685605 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 3	Active, closed	Universitätsmedizin Mannheim	China
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) NCT06346067 · ClinicalTrials.gov ↗ · Advanced or Metastatic NRAS-mutant Melanoma	Phase 3	Active, closed	Erasca, Inc.	UK, USA
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) NCT05685004 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme of Brain	Phase 2/3	Active, closed	TVAX Biomedical	USA
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680 · ClinicalTrials.gov ↗ · Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor	Phase 2	Active, closed	Pfizer	UK, USA, India
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) NCT04752813 · Glioblastoma, Glioblastoma Multiforme	Phase 2	Active, closed	BPGbio	USA
Newly Diagnosed Glioblastoma NCT04959500 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Active, closed	Sun Yat-sen University	China
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma NCT05440786 · ClinicalTrials.gov ↗ · Sarcoma, Ewing, Neoplasm Metastasis	Phase 2	Active, closed	Eli Lilly and Company	USA
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy NCT06413706 · ClinicalTrials.gov ↗ · Glioma	Phase 2	Active, closed	Eli Lilly and Company	USA
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) NCT03491683 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 1/2	Active, closed	Inovio Pharmaceuticals	USA
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 · ClinicalTrials.gov ↗ · Glioblastoma, Melanoma Stage IV, Breast Cancer	Phase 1/2	Active, closed	Sapience Therapeutics	UK, USA
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma NCT04910022 · ClinicalTrials.gov ↗ · Glioblastoma, Diffuse Glioma	Phase 1/2	Active, closed	Nerviano Medical Sciences	USA
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma NCT06478212 · ClinicalTrials.gov ↗ · IDH1-mutant Glioma, IDH2-mutant Glioma	Phase 1/2	Active, closed	Institut de Recherches Internationales Servier	China
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors NCT04337177 · ClinicalTrials.gov ↗ · Solid Tumors, Neuroblastoma, Rhabdomyosarcoma	Phase 1	Active, closed	Valent Technologies, LLC	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Temozolomide

53 conditions

Glioblastoma13Glioblastoma (GBM)4Rhabdomyosarcoma3Solid Tumors3Ewing Sarcoma3Glioblastoma Multiforme3Recurrent Glioblastoma2GBM2Glioma2Glioblastoma Multiforme (GBM)2Neuroblastoma2Cancer1

All 53 conditions

Condition (as registered)	Trials
Glioblastoma	13
Glioblastoma (GBM)	4
Rhabdomyosarcoma	3
Solid Tumors	3
Ewing Sarcoma	3
Glioblastoma Multiforme	3
Recurrent Glioblastoma	2
GBM	2
Glioma	2
Glioblastoma Multiforme (GBM)	2
Neuroblastoma	2
Cancer	1
Brain and Central Nervous System Tumors	1
Advanced or Metastatic NRAS-mutant Melanoma	1
Colorectal Adenocarcinoma	1
Melanoma, Cutaneous Malignant	1
Advanced Solid Malignancies	1
High-Risk Neuroblastoma	1
Melanoma Stage IV	1
Breast Cancer	1
Prostate Cancer	1
Rhabdoid Tumor	1
Neoplasms	1
Child	1
Adolescent	1
Melanoma (Skin Cancer)	1
Melanoma Stage IIIB-IV	1
Cutaneous Melanoma	1
Unresectable Melanoma	1
Relapsed/Refractory Primary Central Nervous System Lymphoma	1
Small Cell Lung Cancer	1
Newly Diagnosed Glioblastoma	1
Glioblastoma Multiforme of Brain	1
Glioblastoma, IDH-wildtype	1
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype	1
Sarcoma, Ewing	1
Neoplasm Metastasis	1
Endometrial Neoplasms	1
Ovarian Neoplasms	1
Soft Tissue Sarcoma (STS)	1
Diffuse Glioma	1
Progressive Pediatric Brain Cancer	1
Recurrent Glioblastoma, IDH-Wildtype	1
Lymphoma	1
Solid Tumor	1
Precision Medicine	1
Mucosal Melanoma	1
PD-L1 Positive	1
Soft Tissue Sarcoma	1
Primary Central Nervous System Hodgkin Lymphoma	1
IDH1-mutant Glioma	1
IDH2-mutant Glioma	1
Primary Central Nervous System Lymphoma	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	32	17
Clinical trials in China	17	13
Clinical trials in UK	10	7
Clinical trials in Ireland	4	3
Clinical trials in India	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Temozolomide trials

How many clinical trials are testing Temozolomide?

49 current trials in our USA, China, UK, Ireland and India registers name Temozolomide as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Temozolomide trials recruiting patients?

Yes. 29 of the 49 trials are recruiting: 17 with sites in USA, 13 with sites in China, 7 with sites in UK and 3 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Temozolomide clinical trials?

Eli Lilly and Company (3), Second Affiliated Hospital, Zhejiang University, School of Medicine (3), Bristol-Myers Squibb (2) and Nerviano Medical Sciences (2), among 43 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Temozolomide works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Temozolomide works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Temozolomide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Temozolomide clinical trials